Cancer therapeutics in yeast.

Abstract:

:The budding yeast Saccharomyces cerevisiae is a genetically tractable model system with which to establish the cellular target of a given agent and investigate mechanisms of drug action.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Bjornsti MA

doi

10.1016/s1535-6108(02)00160-5

keywords:

subject

Has Abstract

pub_date

2002-10-01 00:00:00

pages

267-73

issue

4

eissn

1535-6108

issn

1878-3686

pii

S1535610802001605

journal_volume

2

pub_type

杂志文章,评审
  • Does CSF1R Blockade Turn into Friendly Fire?

    abstract::In this issue of Cancer Cell, Kumar et al. describe how CSF1R blockade induces not only an expected deprivation of tumor-associated macrophages, but also an accumulation of tumor-infiltrating polymorphonuclear mononuclear cells caused by Cxcl-1 released from cancer-associated fibroblasts. ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2017.10.012

    authors: Greten TF

    更新日期:2017-11-13 00:00:00

  • IRS-1: auditing the effectiveness of mTOR inhibitors.

    abstract::Rapamycin analogs that inhibit mTOR signaling have antitumor activity against certain lymphomas, but treatment of solid tumors has been less encouraging despite inhibition of mTOR function. Two recent papers give insight into the potential use of mTOR inhibitors. O'Reilly et al. provide evidence that poor tumor respon...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/j.ccr.2006.02.027

    authors: Easton JB,Kurmasheva RT,Houghton PJ

    更新日期:2006-03-01 00:00:00

  • A new mode of RAF autoregulation: a further complication in the inhibitor paradox.

    abstract::ERK pathway activation in cells expressing wild-type BRAF is a well-reported, clinically-relevant adverse effect of the otherwise impressive response of BRAF(V600E)-mutated melanomas to RAF inhibitors. In this issue of Cancer Cell, Holderfield and colleagues show that RAF autoinhibition underpins this paradox, further...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2013.04.021

    authors: Hey F,Pritchard C

    更新日期:2013-05-13 00:00:00

  • Frequent Derepression of the Mesenchymal Transcription Factor Gene FOXC1 in Acute Myeloid Leukemia.

    abstract::Through in silico and other analyses, we identified FOXC1 as expressed in at least 20% of human AML cases, but not in normal hematopoietic populations. FOXC1 expression in AML was almost exclusively associated with expression of the HOXA/B locus. Functional experiments demonstrated that FOXC1 contributes to a block in...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2015.07.017

    authors: Somerville TD,Wiseman DH,Spencer GJ,Huang X,Lynch JT,Leong HS,Williams EL,Cheesman E,Somervaille TC

    更新日期:2015-09-14 00:00:00

  • Proteogenomic Characterization of Human Early-Onset Gastric Cancer.

    abstract::We report proteogenomic analysis of diffuse gastric cancers (GCs) in young populations. Phosphoproteome data elucidated signaling pathways associated with somatic mutations based on mutation-phosphorylation correlations. Moreover, correlations between mRNA and protein abundances provided potential oncogenes and tumor ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2018.12.003

    authors: Mun DG,Bhin J,Kim S,Kim H,Jung JH,Jung Y,Jang YE,Park JM,Kim H,Jung Y,Lee H,Bae J,Back S,Kim SJ,Kim J,Park H,Li H,Hwang KB,Park YS,Yook JH,Kim BS,Kwon SY,Ryu SW,Park DY,Jeon TY,Kim DH,Lee JH,Han SU,

    更新日期:2019-01-14 00:00:00

  • Cancer epigenetics is no Mickey Mouse.

    abstract::Epigenetic changes are the most common alterations in human cancer, but it has been difficult to sort out cause and effect from studies of human tumors. Several recent nonlethal mouse models implicate both hypomethylation and loss of imprinting (LOI) in tumor formation, including a paper in this issue of Cancer Cell s...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2005.09.014

    authors: Feinberg AP

    更新日期:2005-10-01 00:00:00

  • Targeting oxidative stress in embryonal rhabdomyosarcoma.

    abstract::Rhabdomyosarcoma is a soft-tissue sarcoma with molecular and cellular features of developing skeletal muscle. Rhabdomyosarcoma has two major histologic subtypes, embryonal and alveolar, each with distinct clinical, molecular, and genetic features. Genomic analysis shows that embryonal tumors have more structural and c...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2013.11.002

    authors: Chen X,Stewart E,Shelat AA,Qu C,Bahrami A,Hatley M,Wu G,Bradley C,McEvoy J,Pappo A,Spunt S,Valentine MB,Valentine V,Krafcik F,Lang WH,Wierdl M,Tsurkan L,Tolleman V,Federico SM,Morton C,Lu C,Ding L,Easton J,R

    更新日期:2013-12-09 00:00:00

  • Her 2 in 1.

    abstract::In this issue of Cancer Cell, Park et al. demonstrate that anti-erbB2 antibody primes adaptive immunity for increased tumor clearance and suggest that chemotherapy may in fact interfere with this process. ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2010.07.009

    authors: Smyth MJ,Stagg J

    更新日期:2010-08-09 00:00:00

  • ROR1C Regulates Differentiation of Myeloid-Derived Suppressor Cells.

    abstract::Myeloid-derived suppressor cells (MDSCs) play a major role in cancer. MDSC expansion is closely associated with tumor progression, but molecular mechanisms of this expansion remain poorly understood. In this issue of Cancer Cell, Strauss and colleagues describe the roles of the nuclear receptor ROR1C in the regulation...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2015.07.007

    authors: Gabrilovich D,Nefedova Y

    更新日期:2015-08-10 00:00:00

  • Targeting the lncRNA SAMMSON Reveals Metabolic Vulnerability in Melanoma.

    abstract::In a recent study, Leucci et al. report a role for the long non-coding RNA SAMMSON in driving mitochondrial function in melanoma. Targeting SAMMSON, the gene of which is frequently co-amplified with MITF, highlights a new cell-type-specific therapeutic vulnerability in melanoma irrespective of BRAF, NRAS, or p53 statu...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2016.04.010

    authors: Goding CR

    更新日期:2016-05-09 00:00:00

  • Glut3 Addiction: A Druggable Vulnerability in Glioblastoma.

    abstract::The link between GBM molecular subtype and response to treatment remains undefined. In this issue of Cancer Cell, Cosset and colleagues define a subpopulation of patients within the proneural/classical subtype sensitive to integrin blockade because of a Glut3 addiction. These findings reveal context-dependent druggabl...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2017.11.017

    authors: Bunda S,Zadeh G,Aldape KD

    更新日期:2017-12-11 00:00:00

  • Vulnerabilities of mutant SWI/SNF complexes in cancer.

    abstract::Cancer genome sequencing efforts have revealed the novel theme that chromatin modifiers are frequently mutated across a wide spectrum of cancers. Mutations in genes encoding subunits of SWI/SNF (BAF) chromatin remodeling complexes are particularly prevalent, occurring in 20% of all human cancers. As these are typicall...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/j.ccr.2014.07.018

    authors: Helming KC,Wang X,Roberts CWM

    更新日期:2014-09-08 00:00:00

  • Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.

    abstract::Activating mutations in BRAF are the most common genetic alterations in melanoma. Inhibition of BRAF by small molecules leads to cell-cycle arrest and apoptosis. We show here that BRAF inhibition also induces an oxidative phosphorylation gene program, mitochondrial biogenesis, and the increased expression of the mitoc...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2013.02.003

    authors: Haq R,Shoag J,Andreu-Perez P,Yokoyama S,Edelman H,Rowe GC,Frederick DT,Hurley AD,Nellore A,Kung AL,Wargo JA,Song JS,Fisher DE,Arany Z,Widlund HR

    更新日期:2013-03-18 00:00:00

  • Dangerous Liaisons: Deviant Endothelium NOTCHes toward Tumor Metastasis.

    abstract::In this issue of Cancer Cell, Wieland et al. uncover a feedback loop in which tumor cells, by augmenting Notch signaling, provoke a senescent and pro-inflammatory state in endothelial cells, promoting neutrophil infiltration, tumor cell adhesion, and metastasis. Interfering with this Notch-dependent crosstalk may be a...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2017.02.016

    authors: Guo P,Rafii S

    更新日期:2017-03-13 00:00:00

  • ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.

    abstract::Here, we show that tumor ADORA1 deletion suppresses cell growth in human melanoma cell lines in vitro and tumor development in vivo in immune-deficient xenografts. However, this deletion induces the upregulation of PD-L1 levels, which inactivates cocultured T cells in vitro, compromises anti-tumor immunity in vivo, an...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2020.02.006

    authors: Liu H,Kuang X,Zhang Y,Ye Y,Li J,Liang L,Xie Z,Weng L,Guo J,Li H,Ma F,Chen X,Zhao S,Su J,Yang N,Fang F,Xie Y,Tao J,Zhang J,Chen M,Peng C,Sun L,Zhang X,Liu J,Han L,Xu X,Hung MC,Chen X

    更新日期:2020-03-16 00:00:00

  • Turning on a dimer: new insights into MLL chimeras.

    abstract::In this issue of Cancer Cell, demonstrate a novel mechanism for the oncogenic activity of MLL chimeric proteins. By providing coiled-coil or other dimerization domains, the cytoplasmic partners of MLL fusion proteins donate a platform for MLL homodimerization, allowing recruitment of accessory factors needed to activa...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/s1535-6108(03)00192-2

    authors: Hsu K,Look AT

    更新日期:2003-08-01 00:00:00

  • A molecular view of anti-ErbB monoclonal antibody therapy.

    abstract::Abnormal activation of the epidermal growth factor receptor (EGFR) and its homolog HER2 (Neu/ErbB2) has been associated with many human cancers, and monoclonal antibodies targeting EGFR and HER2 are effective anticancer therapies. Structural studies of these receptors and antibodies have revealed much about how they f...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2008.03.010

    authors: Leahy DJ

    更新日期:2008-04-01 00:00:00

  • Advancing Cancer Research and Medicine with Single-Cell Genomics.

    abstract::Single-cell sequencing (SCS) has impacted many areas of cancer research and improved our understanding of intratumor heterogeneity, the tumor microenvironment, metastasis, and therapeutic resistance. The development and refinement of SCS technologies has led to massive reductions in costs, increased cell throughput, a...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/j.ccell.2020.03.008

    authors: Lim B,Lin Y,Navin N

    更新日期:2020-04-13 00:00:00

  • PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia.

    abstract::PML/RARalpha is of crucial importance in acute promyelocytic leukemia (APL) both pathologically and therapeutically. Using a genome-wide approach, we identified in vivo PML/RARalpha binding sites in a PML/RARalpha-inducible cell model. Of the 2979 targeted regions, >62% contained canonical PU.1 motifs and >84% of thes...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2009.12.045

    authors: Wang K,Wang P,Shi J,Zhu X,He M,Jia X,Yang X,Qiu F,Jin W,Qian M,Fang H,Mi J,Yang X,Xiao H,Minden M,Du Y,Chen Z,Zhang J

    更新日期:2010-02-17 00:00:00

  • Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.

    abstract::The TIGAR protein has antioxidant activity that supports intestinal tissue repair and adenoma development. Using a pancreatic ductal adenocarcinoma (PDAC) model, we show that reactive oxygen species (ROS) regulation by TIGAR supports premalignant tumor initiation while restricting metastasis. Increased ROS in PDAC cel...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2019.12.012

    authors: Cheung EC,DeNicola GM,Nixon C,Blyth K,Labuschagne CF,Tuveson DA,Vousden KH

    更新日期:2020-02-10 00:00:00

  • No need for constant help: human IgG2 antibodies have an autonomous agonistic activity for immunotherapy of cancer.

    abstract::Agonistic antibodies specific for members of the tumor necrosis factor receptor protein family hold great promise for immunotherapy of cancer. In this issue of Cancer Cell, White and colleagues provide evidence that the human IgG2 subclass may represent a superior backbone for the use of these antibodies in human ther...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2014.12.010

    authors: Lux A,Nimmerjahn F

    更新日期:2015-01-12 00:00:00

  • Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice.

    abstract::The erythroleukemia developed by spi-1/PU.1 transgenic mice is a multistage process characterized by an early arrest of the proerythroblast differentiation followed later on by malignant transformation. Herein, we report the presence of acquired mutations in the SCF receptor gene (Kit) in 86% of tumors isolated during...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2005.11.009

    authors: Kosmider O,Denis N,Lacout C,Vainchenker W,Dubreuil P,Moreau-Gachelin F

    更新日期:2005-12-01 00:00:00

  • Clinically Actionable Strategies for Studying Neural Influences in Cancer.

    abstract::Neuro-glial activation is a recently identified hallmark of growing cancers. Targeting tumor hyperinnervation in preclinical and small clinical trials has yielded promising antitumor effects, highlighting the need of systematic analysis of neural influences in cancer (NIC). Here, we outline the strategies translating ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2020.05.023

    authors: Demir IE,Reyes CM,Alrawashdeh W,Ceyhan GO,Deborde S,Friess H,Görgülü K,Istvanffy R,Jungwirth D,Kuner R,Maryanovich M,Na'ara S,Renders S,Saloman JL,Scheff NN,Steenfadt H,Stupakov P,Thiel V,Verma D,Yilmaz BS,White R

    更新日期:2020-07-13 00:00:00

  • Stressing Out about Cancer Immunotherapy.

    abstract::Stress has long been suspected to negatively influence cancer mortality, yet the molecular mechanisms responsible for this effect have only recently been identified. A new study identifies a stress-induced response in dendritic cells-the activation of the glucocorticoid-inducible transcriptional regulator TSC22D3-as a...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/j.ccell.2019.10.013

    authors: He XY,Ng D,Van Aelst L,Egeblad M

    更新日期:2019-11-11 00:00:00

  • Smoothened variants explain the majority of drug resistance in basal cell carcinoma.

    abstract::Advanced basal cell carcinomas (BCCs) frequently acquire resistance to Smoothened (SMO) inhibitors through unknown mechanisms. Here we identify SMO mutations in 50% (22 of 44) of resistant BCCs and show that these mutations maintain Hedgehog signaling in the presence of SMO inhibitors. Alterations include four ligand ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2015.02.002

    authors: Atwood SX,Sarin KY,Whitson RJ,Li JR,Kim G,Rezaee M,Ally MS,Kim J,Yao C,Chang AL,Oro AE,Tang JY

    更新日期:2015-03-09 00:00:00

  • Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

    abstract::Somatic loss-of-function mutations in the ten-eleven translocation 2 (TET2) gene occur in a significant proportion of patients with myeloid malignancies. Although there are extensive genetic data implicating TET2 mutations in myeloid transformation, the consequences of Tet2 loss in hematopoietic development have not b...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2011.06.001

    authors: Moran-Crusio K,Reavie L,Shih A,Abdel-Wahab O,Ndiaye-Lobry D,Lobry C,Figueroa ME,Vasanthakumar A,Patel J,Zhao X,Perna F,Pandey S,Madzo J,Song C,Dai Q,He C,Ibrahim S,Beran M,Zavadil J,Nimer SD,Melnick A,Godley LA

    更新日期:2011-07-12 00:00:00

  • Differential utilization of two ATP-generating pathways is regulated by p53.

    abstract::A fundamental property of cancer cells is the preferential utilization of glycolysis over aerobic respiration to produce ATP. Renewed interest in understanding the mechanism underlying this metabolic shift in energy production is broadening our understanding of the relationship between cancer and cellular metabolism. ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2006.06.014

    authors: Assaily W,Benchimol S

    更新日期:2006-07-01 00:00:00

  • Sumoylation pathway is required to maintain the basal breast cancer subtype.

    abstract::The TFAP2C/AP-2γ transcription factor regulates luminal breast cancer genes, and loss of TFAP2C induces epithelial-mesenchymal transition. By contrast, the highly homologous family member, TFAP2A, lacks transcriptional activity at luminal gene promoters. A detailed structure-function analysis identified that sumoylati...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2014.04.008

    authors: Bogachek MV,Chen Y,Kulak MV,Woodfield GW,Cyr AR,Park JM,Spanheimer PM,Li Y,Li T,Weigel RJ

    更新日期:2014-06-16 00:00:00

  • A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.

    abstract::Activating mutations in GNAQ/GNA11, encoding Gαq G proteins, are initiating oncogenic events in uveal melanoma (UM). However, there are no effective therapies for UM. Using an integrated bioinformatics pipeline, we found that PTK2, encoding focal adhesion kinase (FAK), represents a candidate synthetic lethal gene with...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2019.01.009

    authors: Feng X,Arang N,Rigiracciolo DC,Lee JS,Yeerna H,Wang Z,Lubrano S,Kishore A,Pachter JA,König GM,Maggiolini M,Kostenis E,Schlaepfer DD,Tamayo P,Chen Q,Ruppin E,Gutkind JS

    更新日期:2019-03-18 00:00:00

  • Senesce to Survive: YAP-Mediated Dormancy Escapes EGFR/MEK Inhibition.

    abstract::Therapeutic resistance is a major challenge in cancer treatment. In this issue of Cancer Cell, Kurppa et al. demonstrated that a senescence-like state enables lung cancer cells to survive dual inhibition of EGFR and MEK. This was mediated by the YAP/TEAD pathway, which drives epigenomic reprogramming and EMT to counte...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2019.12.008

    authors: Bado I,Zhang XH

    更新日期:2020-01-13 00:00:00